Opendata, web and dolomites

CannaPreg

Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for the treatment of schizophrenia and psychotic syndromes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CannaPreg" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2016-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

Excessive activation of the cannabinoid type-1 receptor (CB1) in the brain by synthetic, endogenous or plant-derived (cannabis sativa) cannabinoids can lead to pathological states, which could be ameliorated by blocking receptor signalling. However, due to the large number of functions involving the CB1 receptor, direct CB1 antagonist drugs induce side effects limiting their therapeutic use. During the ERC-StG funded project, we found that a particular endogenous and labile lipid compound, pregnenolone, acts as an allosteric and signal-specific inhibitor of CB1 receptors in the brain. Thus, stable pregnenolone-derivative drugs have been produced to exploit the therapeutic potential of allosteric inhibition of CB1 receptor signalling, which can be used to decrease pathological over-activation of CB1 receptors. One clear pathological state where over-activation of CB1 receptors plays a key role is schizophrenia and psychotic syndromes. Indeed, cannabis and synthetic cannabinoids can induce psychotic states and excessive CB1 receptor signalling has been proposed to participate in the etiopathogenesis of human schizophrenia. Thus, the present project aims at establishing the innovative and commercial potential of this new class of drugs, stable derivatives of pregnenolone, as allosteric inhibitors of the CB1 receptor for the treatment of psychotic syndromes. The following issues will be addressed: 1. Technical activities will identify the compounds with the best therapeutic potential. 2. Market studies will determine the potential competitiveness of these compounds. 3. Additional industry partnerships will be sought for later stages of commercial development. By covering these essential steps bridging a scientific idea from basic research to therapeutic applications, the present project is fully integrated in the spirit of the ERC PoC program and, if successful, will provide key medical, economical and societal benefits to Europe.

 Publications

year authors and title journal last update
List of publications.
2016 J.F. Oliveira da Cruz, L.M. Robin, F. Drago, G. Marsicano, M. Metna-Laurent
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse
published pages: 35-42, ISSN: 0306-4522, DOI: 10.1016/j.neuroscience.2015.05.002
Neuroscience 323 2019-07-23
2015 Edgar Soria-Gómez, Arnau Busquets-Garcia, Fei Hu, Amine Mehidi, Astrid Cannich, Liza Roux, Ines Louit, Lucille Alonso, Theresa Wiesner, Francois Georges, Danièle Verrier, Peggy Vincent, Guillaume Ferreira, Minmin Luo, Giovanni Marsicano
Habenular CB1 Receptors Control the Expression of Aversive Memories
published pages: 306-313, ISSN: 0896-6273, DOI: 10.1016/j.neuron.2015.08.035
Neuron 88/2 2019-07-23
2016 Arnau Busquets Garcia, Edgar Soria-Gomez, Luigi Bellocchio, Giovanni Marsicano
Cannabinoid receptor type-1: breaking the dogmas
published pages: 990, ISSN: 2046-1402, DOI: 10.12688/f1000research.8245.1
F1000Research 5 2019-07-23
2016 Ana Gutiérrez-Rodríguez, Nagore Puente, Izaskun Elezgarai, Sabine Ruehle, Beat Lutz, Leire Reguero, Inmaculada Gerrikagoitia, Giovanni Marsicano, Pedro Grandes
Anatomical characterization of the cannabinoid CB 1 receptor in cell-type-specific mutant mouse rescue models
published pages: , ISSN: 0021-9967, DOI: 10.1002/cne.24066
Journal of Comparative Neurology 2019-07-23
2015 Beat Lutz, Giovanni Marsicano, Rafael Maldonado, Cecilia J. Hillard
The endocannabinoid system in guarding against fear, anxiety and stress
published pages: 705-718, ISSN: 1471-003X, DOI: 10.1038/nrn4036
Nature Reviews Neuroscience 16/12 2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANNAPREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANNAPREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More